Feasibility, Safety and Efficacy of Early Redosing with CD19-Targeted CAR-T Cells in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Valentin Ortiz-Maldonado(Hospital Clínic de Barcelona), Jordan Gauthier(Seattle Cancer Care Alliance), Erik L. Kimble(University of Washington), David G. Maloney(Fred Hutch Cancer Center), Delaney R. Kirchmeier(Fred Hutch Cancer Center), Aiko Torkelson(Fred Hutch Cancer Center), Andrew J. Portuguese(University of Washington), Brian G. Till(University of Washington), Alexandre V. Hirayama(University of Washington), Mazyar Shadman(University of Washington), Emily C. Liang(Fred Hutch Cancer Center), Cameron J. Turtle(The University of Sydney), Jennifer J. Huang(Stanford Medicine), Barbara S. Pender, Kristina Braathen(Fred Hutch Cancer Center)
Transplantation and Cellular Therapy
February 1, 2025
10.1016/j.jtct.2025.01.316
Cited by 0

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
|Blood|2016|743
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
|Blood|2008|719